about the company
This leading-edge biotechnology firm is at the forefront of developing next-generation RNAi and siRNA therapeutics. The organization is dedicated to advancing the field of RNA-based medicine through the development of innovative delivery platforms, with a specific focus on extrahepatic targeting and novel AOC/PCC modalities.
The Singapore-based early discovery team acts as a vital international hub for the firm's research efforts. This group is responsible for the end-to-end advancement of therapeutic programs, driving innovation from initial target identification through to preclinical candidate (PCC) nomination.
...
about the job
Strategic Target Discovery: Spearhead the identification and prioritization of novel hepatic and extrahepatic targets. This includes conducting rigorous feasibility assessments, developing biological rationales, and establishing standardized criteria for target selection.
Precision RNA Design: Oversee the design and optimization of siRNA/RNAi sequences, ensuring peak potency and specificity while rigorously minimizing potential off-target effects.
Next-Gen Modality Innovation: Lead the evaluation and advancement of AOC and PCC platforms to enhance the delivery and efficacy of RNA-based therapeutics.
Experimental Validation: Design and execute sophisticated assays for target validation and in-depth mechanism-of-action (MoA) studies.
Cross-Functional Platform Development: Partner closely with Medicinal Chemistry and Antibody Science teams to co-develop and refine integrated delivery technologies.
Pharmacodynamic Assessment: Establish robust screening protocols to evaluate the potency, specificity, and duration of effect across diverse therapeutic modalities.
Delivery System Exploration: Contribute to the scouting and validation of emerging delivery technologies to expand the therapeutic reach of the RNAi pipeline.
International Portfolio Alignment: Maintain a seamless operational model with the overseas discovery group. This involves synchronizing project timelines, aligning on experimental design, and ensuring transparent, cross-site data sharing.
External Research Management: Direct CRO partnerships, managing everything from initial study design and quality control to data interpretation and milestone delivery.
about the manager/team
Individual contributor role, reporting to Discovery Biology VP
skills and experience required
- Ph.D. in Molecular Biology, Cell Biology, Pharmacology, or a related discipline with minimum 5 years of industry experience in RNAi/siRNA drug discovery.
Target Discovery & Validation: Demonstrated track record in identifying and validating novel targets for RNAi therapeutics, with specific expertise across both hepatic and extrahepatic biological pathways.
Precision Sequence Design: Extensive hands-on experience in siRNA/RNAi sequence optimization, including the expert use of bioinformatics tools for sequence analysis, potency prediction, and off-target mitigation.
Advanced Modality Expertise: Strong preference for candidates with experience in AOC (Antibody-Oligonucleotide Conjugates), PCC (Peptide-Drug Conjugates), or similar complex conjugate technologies.
Scientific Rigor: A deep background in molecular and cellular biology, with a proven ability to design and execute hypothesis-driven research that moves the needle on early-stage programs.
Global Collaboration: Proven success operating within cross-site and cross-cultural environments. You should have experience establishing efficient workflows and "seamless" communication models between geographically distributed R&D teams.
Technical Problem Solving: The ability to independently architect complex experimental designs, interpret multifaceted data sets, and provide creative solutions to technical bottlenecks in the discovery phase.
To apply online please use the 'apply' function, alternatively you may contact at .
(EA: 94C3609/ )
